Conclusively, this study reveals the mechanism by which CD9 promotes ESCC progression and radiation resistance through the AKT/GSK3β pathway, emphasizing its clinical value as a potential radiosensitivity predictor and therapeutic target. This evidence concerns the gene CD9 and esophageal squamous cell carcinoma.